Tesamorelin (10 mg vial)

Tesamorelin (10 mg vial)

Primary use: Reduction of visceral adipose tissue (VAT)

Mechanism / class: Synthetic growth hormone–releasing hormone (GHRH) analog; stimulates endogenous GH secretion

Key effects:

• Increases pulsatile growth hormone release

• Elevates IGF-1 within physiologic range

• Reduces visceral (abdominal) fat

• Preserves lean body mass

• Improves metabolic markers in certain populations

Clinical distinction:
FDA-approved for HIV-associated lipodystrophy; specifically shown to reduce visceral fat, not just overall weight. Unlike direct GH administration, it stimulates the body’s natural GH production, maintaining physiologic feedback regulation.